Physician profile
Mark Shparber
NPI 1982614160
$4,121.38
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.45 · 2021: $1,921 · 2022: $234 · 2023: $227 · 2024: $1,726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,600 · Food and Beverage: $353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,600.00 |
| Food and Beverage | $353.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,800.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $925.00 | 2024 | Imfinzi |
| Beigene USA, INC. | $675.00 | 2024 | Brukinsa |
| Novocure Gmbh | $200.00 | 2022 | |
| Celgene Corporation | $161.24 | 2023-2024 | Reblozyl |
| Epizyme, INC. | $99.00 | 2021 | |
| Glaxosmithkline, LLC. | $83.11 | 2023 | Ojjaara, Zejula, Jemperli |
| E.R. Squibb & Sons, L.L.C. | $45.16 | 2021-2022 | |
| Gilead Sciences, INC. | $34.43 | 2023 | |
| Mirati Therapeutics, INC. | $31.83 | 2024 | Krazati |
| Merck Sharp & Dohme LLC | $23.95 | 2024 | Keytruda |
| Genentech USA, INC. | $18.81 | 2023 | Phesgo, Lunsumio, Gazyva |
| Karyopharm Therapeutics INC. | $12.45 | 2020 | |
| Adc Therapeutics America, INC. | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Shparber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.